1 “... review of available clinical trial data. The same transition probabilities for eliglustat and the ERTs...”

2 “...Given issues with the stability of the sponsor's probabilistic analysis (i.e., wide variation...”

3 “...Given issues with the stability of the sponsor's probabilistic analysis (i.e., wide variation...”

4 “... of $1,505,712 per quality-adjusted life-year (QALY) gained and has a 0% probability of being cost-effective...”

5 “...) of $85,496 per QALY when comparing TCZ plus prednisone with prednisone alone (probabilistic analysis)...”

6 “...) of $85,496 per QALY when comparing TCZ plus prednisone with prednisone alone (probabilistic analysis)...”

7 “... probabilities and the increased risk of lipohypertrophy-related clinical events, costs, and quality of life data...”

8 “...) as adjunct therapies to levodopa. The sponsor's base case was a probabilistic analysis conducted from...”

9

10 “... and oxycodone CR. The manufacturer submitted a probabilistic Markov state-transition cost-utility analysis...”

11 “...) as adjunct therapies to levodopa. The sponsor's base case was a probabilistic analysis conducted from...”

12

13

14 “... compared with attempting administration with IM glucagon. The probabilities of a successful full dose...”

15

16 “... compared with attempting administration with IM glucagon. The probabilities of a successful full dose...”

17

18

19 “... 0.1% plus SOC had a 0.03% probability of being cost-effective compared with SOC alone...”

20 “... 0.1% plus SOC had a 0.03% probability of being cost-effective compared with SOC alone...”